AGL AGILON HEALTH INC revenue, earnings and financials
For the quarter ended June 30, 2026, AGILON HEALTH INC reported revenue of $1.49B (up 7.2% from a year earlier), net income of $18.0M and diluted EPS of $1.04; over the last four quarters revenue was $5.92B and net income −$232M; for the fiscal year ended December 2025 revenue was $5.93B, down 2.1% on the year before.
AGL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $5.93B, gross profit n/a, operating income −$463M, net income −$391M (margin -6.6%), EPS n/a
- Fiscal year ended Dec 2024: revenue $6.06B, gross profit n/a, operating income −$292M, net income −$260M (margin -4.3%), EPS n/a
- Fiscal year ended Dec 2023: revenue $4.32B, gross profit n/a, operating income −$232M, net income −$263M (margin -6.1%), EPS n/a
- Fiscal year ended Dec 2022: revenue $2.39B, gross profit n/a, operating income −$105M, net income −$107M (margin -4.5%), EPS n/a
- Fiscal year ended Dec 2021: revenue $1.52B, gross profit n/a, operating income −$372M, net income −$406M (margin -26.7%), EPS n/a
AGL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.49B (up 7.2% year over year), net income $18.0M, EPS $1.04
- Quarter ended Mar 31, 2026: revenue $1.42B (down 7.3% year over year), net income $48.9M, EPS $2.94
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.57B (up 3.1% year over year), net income −$189M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $1.44B (down 1.1% year over year), net income −$110M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $1.39B (down 5.9% year over year), net income −$104M, EPS −$6.31
- Quarter ended Mar 31, 2025: revenue $1.53B (down 4.5% year over year), net income $12.1M, EPS $0.73
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.52B (up 44.2% year over year), net income −$106M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $1.45B (up 27.6% year over year), net income −$118M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $1.48B (up 38.7% year over year), net income −$30.7M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $1.60B (up 52.2% year over year), net income −$6.06M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.06B (up 185.6% year over year), net income −$230M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $1.14B (up 63.6% year over year), net income −$31.4M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $1.07B (up 59.5% year over year), net income −$16.7M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $1.05B (up 61.3% year over year), net income $16.0M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $370M (up 145.2% year over year), net income −$56.5M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $695M (up 51.5% year over year), net income −$30.7M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $670M (up 34.3% year over year), net income −$20.6M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $653M (up 58.2% year over year), net income $1.23M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $151M, net income −$56.7M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $459M, net income −$35.8M, EPS n/a
AGL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$106M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$57.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$156M, share buybacks $200M
- Fiscal year ended Dec 2022: operating cash flow −$131M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$148M, share buybacks n/a
AGL balance sheet
- Jun 30, 2026: cash $107M, total assets $1.59B, total liabilities $1.36B, shareholders' equity n/a, long-term debt $15.4M
- Mar 31, 2026: cash $140M, total assets $1.50B, total liabilities $1.32B, shareholders' equity n/a, long-term debt $15.3M
- Dec 31, 2025: cash $174M, total assets $1.27B, total liabilities $1.14B, shareholders' equity n/a, long-term debt $15.8M
- Sep 30, 2025: cash $172M, total assets $1.60B, total liabilities $1.29B, shareholders' equity n/a, long-term debt $0
- Jun 30, 2025: cash $171M, total assets $1.71B, total liabilities $1.30B, shareholders' equity n/a, long-term debt $0
- Mar 31, 2025: cash $137M, total assets $1.93B, total liabilities $1.43B, shareholders' equity n/a, long-term debt $0
- Dec 31, 2024: cash $188M, total assets $1.73B, total liabilities $1.26B, shareholders' equity $471M, long-term debt $34.9M
- Sep 30, 2024: cash $148M, total assets $2.09B, total liabilities $1.52B, shareholders' equity $575M, long-term debt $34.9M
What is AGL's revenue?
AGILON HEALTH INC reported $5.92B of revenue over its last four quarters, through June 30, 2026.
Is AGL profitable?
No. AGILON HEALTH INC lost $232M over the last four quarters.